Literature DB >> 24006243

Intolerance to imatinib in gastrointestinal stromal tumors: a case report and a review of literature.

Yousra Akasbi1, Samia Arifi, Sami Aziz Brahmi, Fatima Zahra El Mrabet, Nawfel Mellas, Fatima Zahra Mernisi, Omar El Mesbahi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24006243     DOI： 10.1007/s12029-013-9531-5

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  14 in total

1.  Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P G Casali; J-Y Blay
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.

Authors:  Jian Li; Jing Gao; Jinlin Hong; Lin Shen
Journal:  Future Oncol       Date:  2012-05       Impact factor: 3.404

3.  Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate.

Authors:  Virginia Ferraresi; Caterina Catricalà; Mariangela Ciccarese; Angela Ferrari; Massimo Zeuli; Francesco Cognetti
Journal:  Anticancer Res       Date:  2006 Nov-Dec       Impact factor: 2.480

4.  Desensitization to imatinib in patients with leukemia.

Authors:  Robert P Nelson; Kenneth Cornetta; Kelly E Ward; Srinivasan Ramanuja; Chris Fausel; Larry D Cripe
Journal:  Ann Allergy Asthma Immunol       Date:  2006-08       Impact factor: 6.347

Review 5.  Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors.

Authors:  Jean-Yves Blay; Margaret von Mehren; Martin E Blackstein
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

6.  Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

Authors:  J Verweij; A van Oosterom; J-Y Blay; I Judson; S Rodenhuis; W van der Graaf; J Radford; A Le Cesne; P C W Hogendoorn; E D di Paola; M Brown; O S Nielsen
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

7.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Authors:  Ronald P Dematteo; Karla V Ballman; Cristina R Antonescu; Robert G Maki; Peter W T Pisters; George D Demetri; Martin E Blackstein; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Shreyaskumar Patel; Martin D McCarter; Jonathan A Polikoff; Benjamin R Tan; Kouros Owzar
Journal:  Lancet       Date:  2009-03-18       Impact factor: 79.321

8.  Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.

Authors:  P Reichardt; J-Y Blay; H Gelderblom; M Schlemmer; G D Demetri; B Bui-Nguyen; G A McArthur; S Yazji; Y Hsu; I Galetic; P Rutkowski
Journal:  Ann Oncol       Date:  2012-02-21       Impact factor: 32.976

9.  Efficacy of imatinib mesylate neoadjuvant treatment for a locally advanced rectal gastrointestinal stromal tumor.

Authors:  Kyu Jong Yoon; Nam Kyu Kim; Kang Young Lee; Byung Soh Min; Hyuk Hur; Jeonghyun Kang; Sarah Lee
Journal:  J Korean Soc Coloproctol       Date:  2011-06-30

10.  Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivectrade mark) for Advanced Stage Gastrointestinal Stromal Tumours.

Authors:  Lucy C Scott; Jeff D White; Robin Reid; Fiona Cowie
Journal:  Sarcoma       Date:  2005
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.